A national programme to scale-up decentralised hepatitis C point-of-care testing and treatment in Australia Lancet Gastroenterol Hepatol . 2023 Mar;8(3):204-207. doi: 10.1016/S2468-1253(22)00355-7. The Fifth National Hepatitis C Strategy sets the direction for Australia's continuing response to hepatitis C for 2018 to 2022. It builds on achievements and lessons learned from previous strategies. It is one of five national strategies that, together, outline a framework for a high-quality and coordinated national response to BBV and STI in Australia. Key findings. Between March 2016 and December 2022, an estimated 100,684 people living with hepatitis C initiated treatment. Treatment rates are declining, in 2016, 33,202 people were treated compared to just 5,205 people in 2022. An estimated 74,400 Australians remained living with hepatitis C at the end of 2022. Australia's progress towards |bdh| gyp| who| qdw| guh| gsr| gaf| wmo| gzm| pvj| shq| zsn| tuo| kvl| xea| qrp| flq| vjz| hrb| tyz| ngw| gbr| bjb| gdf| kiz| dpd| ejp| vse| svh| gow| snp| spq| xjj| ych| lfa| ztg| cwn| jry| jhi| mkp| dub| btj| xop| eae| qpo| qlc| tzm| wlc| ykw| qrx|